Eiger BioPharmaceuticals, Inc. (EIGRQ)

Eiger BioPharmaceuticals Revenue

In the year 2023, Eiger BioPharmaceuticals had annual revenue of $15.77M with 16.98% growth. Revenue in the quarter ending December 31, 2023 was $3.80M with 41.06% year-over-year growth.

• Revenue (ttm): $15.77M
• Revenue Growth: +16.98%
• P/S Ratio: 1.17
• Revenue / Employee: $630,920
• Employees: 25
• Market Cap: 18.51M

Revenue Chart

* The company reports in USD currency but revenue data is shown in USD.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	15.77M	2.29M	16.98%
Dec 31, 2022	13.48M	1.34M	11.05%
Dec 31, 2021	12.14M	-	-
Dec 31, 2020	0	-	-
Dec 31, 2019	0	-	-
Dec 31, 2018	0	-	-
Dec 31, 2017	0	-	-
Dec 31, 2016	0	-	-
Dec 31, 2015	0	-	-
Dec 31, 2014	0	-	-
Dec 31, 2013	0	-	-
Dec 31, 2012	0	-	-
Jun 30, 2011	0	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.